ArticleBMJ open2019

Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFEr-RITU2: study protocol.

Luis Sánchez-Trujillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.